Background: Neuromuscular block using subjective monitoring and neostigmine reversal is commonly associated with postoperative residual neuromuscular block. We tested whether a protocol for the management of neuromuscular block that specified appropriate dosing and optimal neostigmine reversal was associated with a reduction in postoperative residual neuromuscular block. Methods: Rocuronium administration was guided by surgical requirements and based on the ideal body weight, with dose reductions for female sex and age >55 yr. Neostigmine was administered in adjusted doses after a train-of-four count of four was confirmed at the thumb. The protocol ensured a minimum of 10 min between neostigmine administration and tracheal extubation. We measured the postoperative residual neuromuscular block in patients undergoing abdominal surgery before and after introduction of the protocol. Pre-specified primary and secondary endpoints were incidence of postoperative residual neuromuscular block and severe postoperative residual neuromuscular block at the time of tracheal extubation, defined as normalised train-of-four ratios <0.9 and <0.7, respectively. Results: The incidence of postoperative residual neuromuscular block at tracheal extubation was 14/40 (35%) for patients managed according to the protocol compared with 22/38 (58%) for patients in the control group, odds ratio of 0.39, and 95% confidence interval of 0.14e1.07; P¼0.068. The incidence of severe postoperative residual neuromuscular block at tracheal extubation showed a highly significant difference, odds ratio¼0.06, and confidence interval of 0.00e0.43; P¼0.001. Conclusions: The incidence of severe postoperative residual neuromuscular block was significantly reduced after the protocol was introduced. Given the limitations inherent in this before-and-after study, further research is needed to confirm these results. Clinical trial registration: NCT02660398.
The majority of anaesthesia providers worldwide manage intraoperative muscle relaxation without the use of quantitative neuromuscular monitoring. 1 Rather, they practice within the limitations of clinical observations that include the subjective evaluation of the twitch response evoked by peripheral-nerve stimulators. With regard to reversal, the use of sugammadex is often limited or restricted, and cholinesterase inhibitors are frequently used. Multiple studies of the use of conventional peripheral-nerve stimulators and neostigmine reversal of intermediate-acting neuromuscular blocking drugs (NMBDs) have documented a high incidence of postoperative residual neuromuscular block (PRNB). 2, 3 A recent multicentre study reported an incidence of PRNB of 64% at the time of tracheal extubation and 57% at arrival to the post-anaesthesia care unit (PACU). 4 In this observational study, anaesthetic management was left at the discretion of the individual anaesthesiologist, and specific practice details were not reported. A previous study demonstrated the benefit of using a protocol for muscle relaxant and subsequent neostigmine administration. 5 The protocol was based on the subjective evaluation of the evoked response of peripheral-nerve stimulation and neostigmine administration at an adductor pollicis train-of-four (TOF) count of 2. Ten minutes after the neostigmine administration, the incidence of TOF ratio <0.7 was 30%. Since the publication of this report, several experts have recommended that neostigmine administration be deferred until a TOF count of 4. 6e9 Moreover, recent reports have highlighted common risk factors for PRNB, notably obesity, sex, and age. 10e16 We designed a prospective cohort study to evaluate an updated protocol for the management of neuromuscular block and reversal, enrolling participants before and after the introduction of the protocol. We hypothesised that implementing this protocol for the management of muscle relaxation and reversal with neostigmine would be associated with a lower risk of PRNB defined as normalised TOF (nTOF) ratio <0.9 at the time of tracheal extubation and of severe residual paralysis, defined as nTOF ratio <0.7 at tracheal extubation.
Methods
The study was approved by the Human Subjects Division of the University of Washington (Seattle, WA, USA) and registered at ClinicalTrials.gov (NCT02660398). Written informed consent was obtained from all participants. This before-and-after study was conducted at two teaching hospitals: Harborview Medical Center and University of Washington Medical Center from January to June 2016. We prospectively enrolled participants with ASA Physical status 1e4 who were free from underlying neuromuscular disorders and scheduled to undergo elective abdominal surgery expected to last <4 h and with anticipated use of NMBDs. The exclusion criteria included age <18 yr, pregnant or lactating women, and nonEnglish-speaking patients.
The initial control period consisted of an observational cohort that was managed at the discretion of the anaesthesia providers. The protocol period consisted of a cohort of patients that was managed according to a standardised protocol for the management of rocuronium and subsequent reversal with neostigmine. The primary providers of anaesthesia for all patients in both periods of the study were certified registered nurse anaesthetists and residents, practising with attending staff supervision. No attempt was made to standardise other aspects of care, such as airway management or general anaesthesia induction and maintenance. All patients received usual anaesthesia care, including standard monitoring with electrocardiography, pulse oximetry, end-tidal carbon dioxide concentration, and non-invasive blood-pressure monitoring.
Control period
Each operating room was equipped with a conventional peripheral-nerve stimulator for TOF monitoring (DigiStim II Nerve Stimulator; Neuro Technology, CCR Medical, Inc., St Petersburg, FL, USA) also capable of delivering 50 and 100 Hz tetanic stimulation. Although no written policy was in place, the use of these conventional nerve stimulators was part of routine practice. Documentation of neuromuscular monitoring data in the electronic anaesthesia record requires manual entry, which was not consistently performed. Quantitative monitoring was not routine and was not used by the anaesthesia providers in this study. During the control period, the frequency of neuromuscular monitoring, the choice and administration of NMBD, and the timing and dose of neostigmine for reversal were at the discretion of the provider.
Protocol for neuromuscular monitoring, and rocuronium and neostigmine use
The protocol recommended the manual assessment of the adductor pollicis TOF count, if feasible, and intraoperative muscle relaxation according to surgical requirement (Table 1) . All rocuronium and neostigmine doses were calculated using the ideal body weight (IBW). Previous studies indicate that NMBDs are more appropriately dosed based on IBW than on total body weight, 10, 11 and high BMI has been identified as a risk factor for PRNB. 12 IBW was defined as 50.0þ2.3 kg in À1 over 5 ft for males and 45.5þ2.3 kg in À1 over 5 ft for females, with intubation dose calculated as 0.6 mg kg À1 (IBW). Doses for females were reduced by 15%, as the ED 95 is lower for females, and females given the same dose as males have a prolonged effect. 13e15 We calculated an additional 1% dose reduction per year over 55 yr of patient age because of previous studies indicating a prolonged effect in the elderly, 14 and age reported as a risk factor for PRNB. 16 The protocol recommended avoiding deep block (complete depression of the TOF response) because there is conflicting evidence that deep block
Editor's key points
Whilst quantitation neuromuscular function monitoring is recommended, subjective qualitative monitoring is more commonly practiced. A protocol for management of neuromuscular block with specified appropriate rocuronium dosing and optimal neostigmine reversal was tested in a small pragmatic before/after study at a single centre. Use of the protocol was associated with a reduction in severe postoperative residual neuromuscular block as assessed by several secondary endpoints. Further studies are needed to test whether rates of residual neuromuscular block can be lowered by implementing such a protocol with specific strategies to maximise adherence.
is of benefit in abdominal surgery. 17, 18 If there was a continued need for muscle relaxation, maintenance doses were recommended when the TOF count reached 3; these were calculated as 25% of the intubation dose rounded up to the next higher 5 mg, except during the last hour of the case when it was rounded down to the next lower 5 mg. At the end of the procedure, a tactile pre-reversal assessment of the thumb response to ulnar nerve stimulation was mandatory. If facial nerve stimulation and evaluation of eye-muscle twitches had been used intraoperatively, a change of site to ulnar nerve stimulation was conducted at the end of the procedure 19 to mitigate against eye-muscle monitoring as a significant risk factor for PRNB. 12 Neostigmine was not administered until the TOF count was 4 at the thumb, as reversal with neostigmine from a lower TOF count is unlikely to yield successful reversal in a timely manner, 20, 21 and experts recommend that reversal with neostigmine be initiated when the TOF count has reached 4. 6e8 We required that both the primary anaesthesia provider (certified registered nurse anaesthetist or resident) and the attending anaesthesiologist agree that the fourth twitch was present. The neostigmine dose was calculated using recommended doses 23 The providers were trained regarding the implementation of the new protocol and instructed to follow the practice suggestions. The research staff assisted the providers with protocol reminders and dose calculations.
Study procedures
All measurements were obtained by one of two investigators (S.R.T. and I.C.N.), and were made in the same manner for all patients by using a TOF-Watch SX acceleromyograph (Bluestar Enterprises, Inc., Portsmouth, NH, USA) connected to a laptop computer for data storage. The anaesthesia providers were blinded to TOF ratio measurements in both periods of the study. Two ECG surface electrodes were placed over the ulnar nerve at the wrist, with the positive electrode 3e4 cm proximal to the negative electrode. A TOF-Watch Hand Adapter ® (Bluestar Enterprises, Inc., Portsmouth, NH, USA) was used for all measurements. Immediately after the induction of general anaesthesia, the TOF-Watch SX was calibrated using its CAL2 mode (which automatically adjusts the sensitivity and supramaximal current), and a baseline measurement was obtained. The baseline and all other measurements were obtained by averaging two measurements separated by at least 15 s. If the initial two measurements were not within the 10% agreement, additional measurements separated by at least 15 s (up to four total) were made and the two closest TOF ratios averaged. After baseline measurements, the research staff disconnected the TOF-Watch SX, but left the surface electrodes in place to be used for measurements after neostigmine reversal. A second pair of measurements was obtained immediately before extubation, and a third pair was obtained on arrival to the PACU. Acceleromyography usually yields inflated TOF ratio values compared with electromyography and mechanomyography. The extent of inflation varies between patients. Some authors have recommended that the postoperative acceleromyographic TOF ratios be normalised to the baseline value obtained before neuromuscular block. 24, 25 This is accomplished by dividing the postoperative measurements by the baseline value. As an example, if the baseline TOF ratio is 1.15 and the raw postoperative TOF ratio is 0.95, then the nTOF ratio is 0.95/1.15¼0.83. Normalisation usually yields lower TOF ratios, and it is more likely to classify observations as positive for PRNB. There is variation in the literature regarding how the TOF ratio is defined for evaluating PRNB: whether raw or normalised values are reported when acceleromyography is used, and whether values are measured at tracheal extubation or in PACU. Whilst there is a consensus that the goal is to reduce the incidence of PRNB defined as percent of cases with TOF ratio <0.9, there is not a clear agreement on which of the four ways of measuring the TOF ratio (raw or normalised, at tracheal extubation, or in PACU) should be used. In order to deal with multiple comparisons, we specified a priori that the primary and secondary outcome measures as the incidence of TOF ratios <0.9 and <0.7, respectively, both using the nTOF ratio at tracheal extubation in order to be comparable with the data obtained in the Residual Curarization and Its Incidence at Tracheal Extubation (RECITE) study. 4 However, a raw TOF ratio at PACU is probably the most commonly used measure, 16,26e28 so we report Supplementary data for additional secondary outcomes using this measurement. We also present the mean TOF ratio as used in prior studies.
5,27
The total dose of NMBD was calculated as rocuronium (mg kg À1 ) per minute of procedure time (excluding seven patients in the control group who did not receive rocuronium). Procedure time for this purpose was defined as the time from the first administration of NMBD until the end of the procedure.
Statistical analysis
As preliminary analyses, we present descriptive statistics [mean (standard deviation) or frequencies] for baseline measures of patient and surgery characteristics. Student's t-test and Fisher's exact test were used to compare measures between the protocol and control groups. Baseline characteristics that differed significantly or have a standardised effect size >0.1 were used as covariates in the sensitivity analyses. Preliminary analyses also compared dose and timing measures of NMBDs and reversal agents between the two groups to examine whether the provider behaviour differed between the two time periods. The main analyses compared the incidence of PRNB between the protocol and control groups using Fisher's exact test. Confidence intervals (CIs, 95%) for the incidence within each group were computed using the CI function in Stata (StataCorp, College Station, TX, USA) with the exact binomial option. CIs on the odds ratio (OR) were computed using the exlogit exact logistic regression function in Stata. T-tests with unequal variances were used to compare the mean TOF ratio between the two groups, and permutation tests were done to validate P-values from the t-tests. The percentage of cases with nTOF ratio <0.9 at tracheal extubation was defined a priori as the primary outcome measure, and other outcomes were considered secondary. Unadjusted P-values are presented for analyses of the primary and secondary outcome measures, and the HolmeBonferroni multiple comparison procedure was applied to determine which P-values were still significant after this multiple comparison adjustment. 29 Sensitivity analyses were done to explore whether the results of the main analyses comparing PRNB in the two groups changed after controlling for potential confounders. These included baseline measures of duration of surgery, BMI, and sex, and also time as measured by sequential case number. Exact logistic regression was used.
We intended to study 40 patients in each of the two study periods. Assuming a baseline incidence of PRNB (nTOF ratio <0.9 at time of extubation) of 64% as reported in the RECITE study, 4 this sample would provide 80% power for an expected incidence of 30% in the intervention group. Based on these assumptions, the width of the confidence interval for incidence of PRNB in the intervention group would be 15% to 45%, and the width of the confidence interval for the odds ratio would be 0.09 to 0.72.
Results
We enrolled 84 patients: 44 in the control period and 40 in the protocol period (Fig. 1) . For two patients in the protocol period, the providers did not adhere to the protocol, and they were excluded from all analyses. One patient did not have a TOF count of 4 at the end of the procedure; however, the providers administered neostigmine when four twitches were confirmed immediately after a 50 Hz tetanic stimulation; thus, this TOF count was obtained during post-tetanic facilitation. The second patient received maintenance doses of rocuronium that were not guided by TOF monitoring or surgical requirements, but were apparently administered to control 'curare clefts' (i.e. respiratory effort as evident in the capnogram). Amongst the remaining 82 patients, three had no TOF ratio data at either extubation or PACU because of unavailability of research staff, leaving 79 patients (38 control and 41 protocol). This number includes five patients with TOF ratio measured at tracheal extubation, but not at PACU, and one patient with TOF ratio measured at PACU, but not at tracheal extubation.
Patient and surgery characteristics
The mean age was 56 yr (15) and the mean BMI was 32 kg m À2 (10). Forty-five (58%) patients were female, and the distribution of ASA Physical status was 4 (5%), 29 (37%), 44 (56%), and 1 (1%) for ASA 1, 2, 3, and 4, respectively. The distribution by surgical procedure was 61 (78%), 10 (13%), and seven (9%) for laparoscopic, open abdominal, and laparoscopic converted to open, respectively. The mean surgery duration was 177 (83) min. None of these characteristics differed significantly between groups; however, three characteristics had standardised difference >0.1: duration of surgery (30 min longer in the protocol group; P¼0.11), BMI (2.6 kg m À2 higher in protocol; P¼0.27), and gender (12% more females in protocol; P¼0.36), and hence, could be considered potential confounders.
Neuromuscular blocking and other drugs during surgery
Rocuronium, vecuronium, and cisatracurium were administered to 82%, 10%, and 8% in the control group. All patients in the protocol group received rocuronium. Eight patients in each group (21% and 20%, respectively) received succinylcholine for intubation followed by a NMBD for the remainder of the case.
The use of antibiotics other than b-lactam agents was as follows for the control and protocol groups, respectively: vancomycin (three and zero), clindamycin (five and three), and aminoglycosides (one and zero). One patient in each group received total i.v. anaesthesia. In all other patients, anaesthesia was maintained with inhalation agents, with sevoflurane used in all but four patients in the protocol group who received isoflurane. The groups did not differ significantly in the following measured time intervals: last dose of NMBD to neostigmine administration, last dose of NMBD to extubation, neostigmine to extubation, and extubation to PACU ( Table 2 ). The last dose , respectively]. An expanded Table 2 , including the median, range, and interquartile range, is available as Supplementary data. For patients who received rocuronium for intubation, the intubating dose of rocuronium was 50 mg or higher in 12% of patients in the protocol period vs 68% in the control period, and >0.8 mg kg À1 in none of the patients in the protocol period vs 44% in the control period. In the protocol period, the neostigmine dose never exceeded 60 or 80 mg kg
À1
, whilst this was the case for 26% and 9% of patients, respectively, in the control period. The time between neostigmine administration and extubation was 1.4 min longer in the protocol compared with the control period (17.0±5.4 vs 15.6±11.1 min, respectively; P¼0.51).
The eye muscles were used for pre-reversal assessment in none of the patients in the protocol group and 13/35 (37%) of patients in the control group. The last TOF count was collected in all but two cases in the control group, and the final TOF count before reversal was <4 in six/36 cases in the control period and zero/40 cases in the protocol period. The monitoring site and TOF count for these six control cases were two patients monitored at the eye muscles with a TOF count of 3, one patient monitored at the eye muscles with a TOF count of 2, one patient monitored at the thumb with a TOF count of 1, and two patients with an unknown monitoring site with a TOF count of 3.
Analysis of post-reversal neuromuscular block
There was a fairly good agreement between the two averaged TOF ratio values. The median absolute differences were 3 and 4, and the intra-class correlations were 0.98 at extubation and 0.95 in PACU. A plot of nTOF ratio at tracheal extubation for all subjects (Fig. 2) , with sequence number of study entry on the x-axis, shows that low values of nTOF ratio were more common in the control group on the left (blue circles) than in the protocol group on the right (red triangles). The primary outcome measure, namely, the incidence of PRNB defined as nTOF ratio <0.90, is shown as points below the dashed line. The statistical analyses showed that the pre-specified primary outcome measure, the incidence of PRNB at tracheal extubation as defined by nTOF ratio <90%, was lower in the protocol than in the control group (35% vs 58%), but the difference was not statistically significant (P¼0.068; Table 3 ) with a wide CI for the OR. The pre-specified secondary outcome, the incidence of severe PRNB at tracheal extubation defined as nTOF ratio <70%, was much lower in the protocol than in the control group. Additional secondary outcome measures showed statistically significant differences between the groups (see Supplementary data), and applying the HolmeBonferroni procedure showed that all outcomes except the pre-specified primary outcome measure remained significant after accounting for multiple comparisons. No patients in the protocol group had severe PRNB on admission to the PACU compared with seven (21%) in the control group, with an OR for severe PRNB at PACU of 0.00 and CI of 0.00e0.54. The measure of raw TOF ratio <0.9 upon PACU arrival, the most commonly reported acceleromyographic measure, 16,26e28 showed a large difference between groups with an incidence of zero in the protocol group compared with 13 (38%) in the control group (P<0.001; OR¼0.00 with CI of 0.00e0.20).
The normalised values of the TOF ratio were slightly lower than the raw values (seen by comparing Supplementary  Fig. S1a and b, and c and d) . As a number of points are close to the dashed line at 0.9 in the top two panels, this small shift has a big impact on the estimated incidence of PRNB at tracheal extubation using <0.9 as the criterion, at least in the protocol group. Analyses based on the mean TOF ratio are less sensitive to this small shift as a result of normalisation. Complete results for all measures are included in Supplementary Table S1 .
Sensitivity analysis of controlling for potential confounders
Three baseline measures were identified as potential confounders. Duration of surgery, BMI, and gender differed somewhat between groups with standardised effect size >0.1, although none of these differences were statistically significant. Sensitivity analyses on the primary outcome measure using exact logistic regression found that controlling for duration of surgery or BMI produced a statistically significant difference between the protocol and control groups at risk of PRNB (P¼0.035 and 0.048, and OR¼0.33 and 0.37, respectively). Controlling for gender led to almost no change (OR¼0.39; P¼0.065) and controlling for all three of these potential confounders together gave OR¼0.27 (CI 0.08e0.84; P¼0.020). Sensitivity analyses of the secondary outcome measures showed similar results. Three patients in the control group received cisatracurium. When restricting the analysis only to patients who received rocuronium, the results were not substantially different.
No serious complications, such as airway obstruction or need for assisted ventilation, were identified in either group. PACU nurses and anaesthesia providers were verbally notified immediately whenever the investigator identified severe residual paralysis. The patients were not clinically tested with head lift, grip strength, etc.; however, no patient exhibited clinical signs or symptoms of weakness. Patients with the most severe residual paralysis in the control group were managed with routine oxygen by open face mask and close supervision by PACU nurses. There were no significant differences between groups in the occurrence of respiratory failure (two protocol and one control), pulmonary oedema (one protocol and one control), or reintubation within 7 days (one protocol and zero control). There were no cases of pneumonia, unplanned ICU admission, or deaths within 30 days.
In exploratory analyses, we compared the two groups with regard to PACU length of stay (LOS). Time in PACU, defined as minutes from PACU admission up to the time of meeting criteria for discharge, was not significantly different in the protocol period [mean LOS 137 (88) 
Discussion
We examined the effect of following a protocol for management of neuromuscular block with rocuronium and reversal with neostigmine based on expert recommendations. The protocol did not include quantitative monitoring nor did it include the use of sugammadex, in line with widespread practice. The protocol had two main components: appropriate administration of rocuronium with dose adjustments for age, gender, and BMI, and emphasis of the importance of adequate spontaneous recovery by confirming a TOF count of 4 at the thumb before reversal with allowance of a minimum of 10 min after neostigmine administration before extubation to achieve its peak effect. Table 3 Incidence of residual paralysis and severe residual paralysis before and after the introduction of the protocol. CI, 95% confidence interval based on exact binomial for percent or exact logistic regression for odds ratio; nTOFR, normalised train-of-four ratio; PACU, post-anaesthesia care unit; PRNB, postoperative residual neuromuscular block; P1, P-value based on Fisher's exact test; P2, Pvalue based on exact logistic regression controlling for duration of surgery, BMI, and gender; TE, tracheal extubation. * Primary outcome measure. Compared with the control period during which management was left at the discretion of the anaesthesia providers, the incidence of PRNB at tracheal extubation did not differ significantly with the use of the protocol. However, the prespecified secondary outcome showed less severe PRNB at tracheal extubation with the protocol. Pocock and Stone 30 argue that 'the interpretation of any trial should depend on the totality of the evidence (i.e. the primary, secondary, and safety outcomes), not just a single end point'. In the current study, we analysed 12 outcome measures (i.e. 12 different ways of quantifying residual paralysis). Eleven of the 12 showed statistically significantly lower PRNB with the protocol compared with the control period even after adjustment for multiple comparisons. The other outcome, which is the one we had pre-specified as the primary outcome, showed a substantial difference that was not quite statistically significant (P¼0.068). Following the advice of Pocock and Stone, 30 we feel it is appropriate to conclude that these results provide strong evidence that our protocol is associated with a reduction in the incidence of PRNB. Given the small size of this study, this will need to be confirmed in other studies. Our findings substantially validate previously made recommendations for practice within the limitations of subjective peripheral-nerve stimulators and reversal with neostigmine. 31 Subjective monitoring with the use of cholinesterase inhibitors is associated with a high incidence of postoperative PRNB, currently defined as TOF ratio <0.9. In a meta-analysis, the pooled estimated incidence of PRNB was 34.8% (95% CI 13e61%) for patients who were administered intermediateacting NMBDs and managed with subjective neuromuscular monitoring. 32 The studies in this meta-analysis used a methodology for the primary outcome assessment that differed in several respects from the one used in RECITE and in our study. First, they reported TOF ratios after admission to the PACU and not at tracheal extubation. Second, normalisation or other approaches to dealing with the inflated raw values from acceleromyography were not used. Therefore, it should be expected that our methodology will yield a substantially higher incidence of residual paralysis. The incidence of PRNB on arrival to the PACU was very low; in fact, we did not observe any cases of PRNB in the protocol period when using raw (nonnormalised) measurements. These have been used in several previous studies, some of which are important outcome studies that have highlighted the association between PRNB and adverse clinical outcomes. 26e28 For example, Murphy and colleagues 27 reported that patients in the intervention group randomised to intraoperative acceleromyographic monitoring had a reduced incidence of PRNB of 4.5%. PRNB was defined as a raw (non-normalised) TOF ratio <0.9 on arrival to the PACU; the comparable result from our protocol period was 0%. In the study by Murphy and colleagues, 27 the intervention group had improved clinical outcomes, no patient required an active intervention to maintain a patent airway, had severe hypoxaemia during transport to the PACU, or had severe hypoxaemia during the first 30 min in the PACU. We did not study clinical outcomes; however, clearly, the methodology, and specifically the definition of PRNB, in our study (and RECITE) represents a 'high standard', and the results should be interpreted accordingly. We intentionally adopted the methodology of the RECITE study for the assessment of the primary outcome, so that our results can be directly compared. However, using the different definitions of PRNB from previous studies for our secondary analyses produced very significant results with PRNB much lower in the protocol period than in the control period. The incidence of PRNB in our control period was 58%, which is generally consistent with the value of 63.5% in the RECITE study, 4 and also consistent with the value of 57.8% in the RECITE China study. 33 The incidence of severe residual paralysis (TOF ratio <0.7) in our control group was 32%, which is consistent with the 33.6% incidence in the RECITE study and 29.8% in the RECITE China. Similar to the two RECITE studies, we did not standardise the type of anaesthetic management. Our protocol included current recommendations by leading experts in the field.
6e8, 19, 34 We also included dose adjustments for obesity, gender, and age to mitigate these known risk factors for PRNB. We found in a previous study that a high BMI was associated with a more than three-fold increased risk of PRNB, 12 presumably because of overdosing of NMBDs for obese patients. Female gender has also been reported as a risk factor for PRNB, 15, 35 and females require 20e30% lower doses of vecuronium and rocuronium than males. 13, 14, 36, 37 In the absence of a consensus regarding dose adjustment for female patients, we used a dose reduction for female patients of 15%. Likewise, age has been reported to be a risk factor for PRNB, 16 and the elderly requires lower doses of vecuronium and rocuronium. We speculate that similar to inadequate dose adjustment for age with volatile agents, there is a frequent inadequate dose adjustment of NMBDs for elderly patients. 38 In the absence of a consensus regarding dose adjustment for elderly patients, we reduced the doses by 1% for each year over age 55 yr.
The requirement for pre-reversal assessment obtained from adductor pollicis is critical. Although this has been recommended for several years, 19 our providers often felt that this required a significant change from their routine practice. It is notable that this requirement would be equally important if reversal is accomplished with sugammadex, because the current dose recommendations were developed based on the evaluation of the adductor pollicis response and are not applicable when reversal is guided by eye-muscle monitoring. 39 Previous research has demonstrated that administering neostigmine at a TOF count of 4 is significantly more likely to yield satisfactory and timely reversal compared with a lower TOF count. However, it is also clear from previous research that a successful reversal is not guaranteed even when the spontaneous recovery has progressed to a TOF count of 4. Only when the TOF ratio is 0.40, which often correlates with a TOF count of 4 without subjectively appreciated fade, did all patients in a study cohort achieve a timely successful reversal as defined by a TOF ratio >0.9 within 10 min of neostigmine administration. 40 As this protocol involved a bundled intervention, we do not know which of the several components of the protocol contributed most to the improved outcome. The confirmation of a TOF count of 4 at the thumb before the administration of neostigmine, and ensuring that at least 10 min elapse after neostigmine before extubation, can be considered especially important because these steps represent 'the final common pathway' within this protocol. However, the preceding components of the protocol are also essential, because they serve to avoid overdosing and allow clinicians to confirm the required TOF count of 4 in a timely manner, thus facilitating protocol adherence. Note that the last dose of rocuronium was substantially lower during the protocol period (mean 195 mg kg À1 ) than the control period (483 mg kg À1 ; Table 2 ).
The protocol was associated with reduced doses of both rocuronium and neostigmine. The patients in our study had a mean age that was 8 yr older than those in RECITE, and our patients had a higher BMI (~5 kg m À2 higher than the mean BMI of the RECITE cohort).
Therefore, our cohort might have been at greater risk of PRNB. Quantitative neuromuscular monitoring is required to prevent PRNB reliably, and we agree with the recommendation for its routine use. 46e48 However, the implementation of quantitative monitoring has been slow, and the majority of anaesthesiologists around the world are providing care without quantitative monitoring and sugammadex. Thus, we felt it is important to test a practical protocol for care within the limitations of cholinesterase inhibitors and subjective neuromuscular monitoring. We believe that our study demonstrates one immediately available approach to improving care. We also believe that our study is an important complement to studies that have reported results from practice using neostigmine without a protocol, and sometimes comparing this to a protocol based on sugammadex. 49, 50 The use of sugammadex alone, without guiding dosing by neuromuscular monitoring and a valid pre-reversal assessment of the adductor pollicis response, did not yield acceptable outcomes. 51 The trend towards shorter time in the PACU is intriguing and seems to be driven by a larger number of patients with relatively short PACU stays in the protocol compared with the control period ( Supplementary Fig. S2 ). It is conceivable that better management of neuromuscular block and its reversal might have contributed to expedited discharge criteria readiness. These data support previous findings on the association between PRNB and PACU LOS. 52 
Limitations
Our study has several limitations. The sample size is relatively small; a larger study would provide narrower CIs on the estimates of the rate of PRNB. Being observed by the research assistant in the operating room might have led the providers to attempt to improve care and decrease the risk of PRNB for study patients, especially in the control group. This could have led to outcomes in the control group that were better than they would have been otherwise, which could bias the results towards a smaller difference between the two periods. In contrast, being observed during the protocol period might have led to better adherence to the protocol than would occur in routine clinical practice. Not all providers agreed to participate in the second period of the study, which involved following the protocol. If the providers who did participate in the second period were more skilled at managing NMBDs and their reversal than those who participated in the control period, then this could have biased the results towards a greater difference between the two periods. The frequency of TOF count measurements was not recorded by the observer and is not usually charted by providers; hence, we are unable to report this. As this was not a randomised trial with a concurrent control group, it is possible that measured or unmeasured patient characteristics could have differed between the two time periods. The sensitivity analyses found that controlling for surgery duration, BMI, and gender led to moresignificant results, although the change was relatively small. For all of these reasons, replicating these results in a large randomised clinical trial would be desirable. Ideally, this trial should use a group randomised approach, with randomisation assignment at the hospital level, as to minimise 'contamination' between groups. It would also be important to develop and evaluate practical methods for ensuring that providers follow the protocol. Furthermore, future studies should also prospectively capture pulmonary complications that this study was not designed to address. We did not systematically study surgeon satisfaction with intraoperative muscle relaxation.
The role of adequate spontaneous recovery is obviously important for reversal with neostigmine, and the protocol required that the fourth twitch had reappeared before the administration of neostigmine; however, we did not use continuous monitoring and do not know for how long the fourth twitch had been present at the time of reversal. Nor did we make a quantitative assessment of the fourth twitch at the time of reversal, and therefore, cannot report how often it was 'strong' or 'weak'. A 5 s, 50 Hz tetanic stimulation followed by 2e5 min of TOF stimulation should be applied before the calibration of the TOF-Watch SX to achieve baseline signal stabilisation, which was not done in this study.
The patients in this study had abdominal surgery, and this likely represents a relatively challenging category of surgical patients because of the frequent need for continuous muscle relaxation through fascial closure, after which the case is often quickly completed. The protocol could be more or less feasible to implement depending on many factors, including type of surgical procedures, and these factors were not studied.
Our study assessed protocol implementation on a perprotocol basis. Further research will be needed to test whether the rates of PRNB can be lowered by implementing specific strategies to maximise adherence to the protocol, with analysis on an intent-to-treat basis.
Conclusions
For anaesthesia providers who are practising within the limitations of subjective monitoring and neostigmine reversal, adherence to a protocol for the management of perioperative muscle relaxation and reversal with neostigmine is associated with a substantial reduction in residual paralysis. Important aspects of the protocol are to avoid overdosing and to confirm adequate spontaneous recovery by obtaining a valid prereversal assessment of the adductor pollicis response. Our results support the recommendation that neostigmine reversal in the context of volatile anaesthesia and subjective monitoring should not be administered before the reappearance of the fourth twitch in the TOF response.
